Book contents
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- 10 HER
- 11 The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
- 12 TGF-β signaling in stem cells and tumorigenesis
- 13 Platelet-derived growth factor
- 14 FMS-related tyrosine kinase 3
- 15 ALK: Anaplastic lymphoma kinase
- 16 The FGF signaling axis in prostate tumorigenesis
- 17 Hepatocyte growth factor/Met signaling in cancer
- 18 PI3K
- 19 Intra-cellular tyrosine kinase
- 20 WNT signaling in neoplasia
- 21 Ras
- 22 BRAF mutations in human cancer: biologic and therapeutic implications
- 23 Aurora kinases in cancer: an opportunity for targeted therapy
- 24 14-3-3 proteins in cancer
- 25 STAT signaling as a molecular target for cancer therapy
- 26 The MYC oncogene family in human cancer
- 27 Jun proteins and AP-1 in tumorigenesis
- 28 Forkhead box proteins: the tuning forks in cancer development and treatment
- 29 NF-κB and cancer
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
19 - Intra-cellular tyrosine kinase
from Part 2.1 - Molecular pathways underlying carcinogenesis: signal transduction
Published online by Cambridge University Press: 05 February 2015
- Frontmatter
- Dedication
- Contents
- List of Contributors
- Preface
- Part 1.1 Analytical techniques: analysis of DNA
- Part 1.2 Analytical techniques: analysis of RNA
- Part 2.1 Molecular pathways underlying carcinogenesis: signal transduction
- 10 HER
- 11 The insulin–insulin-like growth-factor receptor family as a therapeutic target in oncology
- 12 TGF-β signaling in stem cells and tumorigenesis
- 13 Platelet-derived growth factor
- 14 FMS-related tyrosine kinase 3
- 15 ALK: Anaplastic lymphoma kinase
- 16 The FGF signaling axis in prostate tumorigenesis
- 17 Hepatocyte growth factor/Met signaling in cancer
- 18 PI3K
- 19 Intra-cellular tyrosine kinase
- 20 WNT signaling in neoplasia
- 21 Ras
- 22 BRAF mutations in human cancer: biologic and therapeutic implications
- 23 Aurora kinases in cancer: an opportunity for targeted therapy
- 24 14-3-3 proteins in cancer
- 25 STAT signaling as a molecular target for cancer therapy
- 26 The MYC oncogene family in human cancer
- 27 Jun proteins and AP-1 in tumorigenesis
- 28 Forkhead box proteins: the tuning forks in cancer development and treatment
- 29 NF-κB and cancer
- Part 2.2 Molecular pathways underlying carcinogenesis: apoptosis
- Part 2.3 Molecular pathways underlying carcinogenesis: nuclear receptors
- Part 2.4 Molecular pathways underlying carcinogenesis: DNA repair
- Part 2.5 Molecular pathways underlying carcinogenesis: cell cycle
- Part 2.6 Molecular pathways underlying carcinogenesis: other pathways
- Part 3.1 Molecular pathology: carcinomas
- Part 3.2 Molecular pathology: cancers of the nervous system
- Part 3.3 Molecular pathology: cancers of the skin
- Part 3.4 Molecular pathology: endocrine cancers
- Part 3.5 Molecular pathology: adult sarcomas
- Part 3.6 Molecular pathology: lymphoma and leukemia
- Part 3.7 Molecular pathology: pediatric solid tumors
- Part 4 Pharmacologic targeting of oncogenic pathways
- Index
- References
Summary
Introduction
Protein kinases are proteins that enzymatically add a phosphate, obtained from ATP, to an OH group on certain amino acids in a protein. They are divided into two major groups: serine/threonine kinases phosphorylate serine or threonine residues; tyrosine kinases phosphorylate tyrosine residues (1). Dual-specificity kinases, such as Mek, phosphorylate all three amino acid residues. Phosphorylation causes a conformational change in the target protein by the addition of a bulky, charged group (Figure 19.1) to the protein. This causes alteration of the activity, subcellular location, or protein–protein interactions of phosphorylated proteins.
Phosphorylation is a rapid method of activating and inactivating proteins and significantly altering pathway activities. Phosphorylation regulates cell adhesion, cell-cycle progression, transcription-factor activity, and general metabolism in the cell. As a result, phosphorylation events must be tightly regulated. Most tyrosine kinase targets have an associated protein phosphatase, designed to reverse the effects of phosphorylation rapidly. Often phosphorylation results in the addition or removal of a regulatory protein that either interferes with binding of the target protein to a substrate or maintains it in a separate subcellular compartment away from the substrate. Perturbation of the pathways can cause dysregulation of cellular activities and lead to a number of disorders, including malignancy. It has been stated that cancer is fundamentally a disease of aberrant kinase activity and signal transduction (2).
- Type
- Chapter
- Information
- Molecular OncologyCauses of Cancer and Targets for Treatment, pp. 231 - 242Publisher: Cambridge University PressPrint publication year: 2013